FIELD: medicine.
SUBSTANCE: invention relates to an intermediate compound of an antibody-drug conjugate containing SN38, and a method for production thereof. Water-soluble group of PEG, having biological activity, is introduced into linker structure and structural modification of PEG is carried out. Method is simple and cheap and environmentally safe since heavy metal ions are not involved in the reaction.
EFFECT: as compared to antibody-drug conjugate intermediate compounds in which SN38 is a toxin in existing technology, use of the intermediate compound of the antibody-drug conjugate synthesized by said method provides higher stability and efficacy.
24 cl, 3 dwg, 6 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODY-DRUG CONJUGATE LOADED WITH BINARY TOXINS AND ITS USE | 2021 |
|
RU2795148C2 |
| LINKER FOR ANTIBODY-DRUG CONJUGATES AND THEIR USE | 2019 |
|
RU2792201C2 |
| COVALENT LINKERS IN ANTIBODY-DRUG CONJUGATES, METHODS FOR PREPARING THEM AND USE THEREOF | 2016 |
|
RU2698727C1 |
| OLIGOPEPTIDE LINKER INTERMEDIATE AND METHOD FOR PRODUCTION THEREOF | 2019 |
|
RU2775973C1 |
| ANTIBODY-DRUG CONJUGATE HAVING AN ACID SELF-STABILIZING BINDING SITE | 2018 |
|
RU2793125C2 |
| METHOD FOR PRODUCING AN ANTIBODY-DRUG CONJUGATE INTERMEDIATE COMPOUND | 2019 |
|
RU2724436C1 |
| NOVEL ANTIBODY CONJUGATES AND USES THEREOF | 2014 |
|
RU2684468C2 |
| COMPOUNDS WHICH INCLUDE SELF-SPLITTING GROUP | 2015 |
|
RU2712744C2 |
| EFFICACY OF CONJUGATES OF ANTI-TROP-2 ANTIBODY WITH DRUG SN-38 FOR THERAPY OF RECURRENT/REFRACTORY TO INHIBITORS OF TUMOR CONTROL POINT | 2017 |
|
RU2725292C2 |
| ONE-REACTOR METHOD FOR OBTAINING AN ANTIBODY-DRUG CONJUGATE INTERMEDIATE PRODUCT | 2020 |
|
RU2745738C1 |
